Capital Advisors, Ltd. LLC Akebia Therapeutics, Inc. Transaction History
Capital Advisors, Ltd. LLC
- $793 Million
- Q4 2024
A detailed history of Capital Advisors, Ltd. LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Capital Advisors, Ltd. LLC holds 320 shares of AKBA stock, worth $784. This represents 0.0% of its overall portfolio holdings.
Number of Shares
320
Previous 320
-0.0%
Holding current value
$784
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
128Shares Held
63.3MCall Options Held
50.6KPut Options Held
203K-
Black Rock Inc. New York, NY11.6MShares$28.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$26.7 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$15.4 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$14.1 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$11.7 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $450M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...